Decoy Therapeutics (DCOY) Stock Price, News & Analysis

Company Overview

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Key Stats

• Today's Range: $5.49 to $6.04
• 50-Day Range: $4.41 to $8.92
• 52-Week Range: $4.32 to $415.80
• Volume: 5,227 shs
• Average Volume: 13,592 shs
• Market Capitalization: $2.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Hold

Decoy Therapeutics Stock Analysis - MarketRank™

Decoy Therapeutics scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Decoy Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Decoy Therapeutics has a consensus price target of $30.00, representing about 443.5% upside from its current price of $5.52.

Amount of Analyst Coverage

Decoy Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Decoy Therapeutics are expected to decrease in the coming year, from ($12.97) to ($19.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Decoy Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Decoy Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Decoy Therapeutics has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.38% of the float of Decoy Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Decoy Therapeutics has a short interest ratio ("days to cover") of 0.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Decoy Therapeutics has recently decreased by 78.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Decoy Therapeutics does not currently pay a dividend.

Dividend Growth

Decoy Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.43

News Sentiment

Decoy Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Decoy Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Decoy Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of Decoy Therapeutics is held by insiders.

Percentage Held by Institutions

11.88% of the stock of Decoy Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 6/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DCOY
• CIK: 1615219
• Web: N/A
• Phone: (346) 772-0346
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Decoy Therapeutics: $30.00
• High Price Target: $30.00
• Low Price Target: $30.00
• Potential Upside/Downside: +443.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($106.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -395.42%
• Return on Assets: -193.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.84
• Quick Ratio: 1.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.07 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 532,000
• Free Float: 523,000
• Market Cap: $2.94 million
• Optionable: N/A
• Beta: 0.57